NCT02543788

Brief Summary

Patients with multiple sclerosis (MS) may show chronic signs of optic neuropathy (CON) that may follow acute optic neuritis (secondary form of CON, S-CON) or occur independently of any acute demyelinating lesion of the optic nerve (primary form of CON, P-CON). In both S-CON and P-CON, a long term progressive ganglion cell axonal loss occurs. This axonal damage could be secondary to retrograde atrophy of axons within plaques of demyelination or a primary progressive degeneration of ganglion cells, but the underlying physiopathology has not been fully questioned in the different profile types of CON. In this project, investigators aim at understanding the pathophysiology of S-CON and P-CON, i.e. secondary to demyelination or primary degeneration, in patients complaining of persistent visual complaints. In a first cross sectional study, 30 MS patients with mild to moderate P-CPON or S-CON and 30 age-matched control subjects will perform an extensive neuro-ophthalmological assessment including clinical examination, visual evoked potentials (pattern and low contrast), electroretinogram (pattern and multifocal ERG), OCT (peripapillary and macular volume scan segmentation protocols) and MRI of the optic nerve. In these patients with mild to moderate CON, investigators aim at differentiating patients showing predominant demyelination from those showing pure or predominant axonal degeneration. Visual function assessment and degree of axonal degeneration will be compared and correlated in the two types of underlying pathophysiology and in the group of control subject. In a following longitudinal study, the patients will be re-assessed a year later in order to evaluate the progression of CON in both profile types. Our hypothesis would be that visual function and progression is worse in the degeneration group as compared to the demyelination group. This study should help to find reliable measures of the pathophysiology of CON and correlate it with the long-term visual prognostic of the disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 25, 2014

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2014

Completed
1 year until next milestone

First Posted

Study publicly available on registry

September 7, 2015

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2016

Completed
Last Updated

September 3, 2025

Status Verified

August 1, 2025

Enrollment Period

1.9 years

First QC Date

June 25, 2014

Last Update Submit

August 26, 2025

Conditions

Keywords

optic neuritisvisionquality of lifepathophysiology

Outcome Measures

Primary Outcomes (1)

  • Change from Day0 15' P100 VEP latency at one year

    15' VEP latency may be the best outcome that allow differentiating patients from controls, and each of the sub-group of patients

    D0 and one year

Secondary Outcomes (6)

  • Change from Day0 100%, 2.5% and 1.25% ETDRS Visual Acuity at one year (composite measure)

    D0 and one year

  • Change from Day0 Visual field macular threshold and corrected mean visual field deficit at one year (composite measure)

    D0 and one year

  • change frome Day0 NEI-VFQ 25 composite score and 10-item score at one year (composite measure)

    D0 and one year

  • Change from Day0 N75, P100, N135 VEP latency and amplitude; P50, N95 ERG latency and amplitude; p1 mERG latency and amplitude at one year (composite measure)

    D0 and one year

  • Change from Day0 OCT peripapillary RNLF thickness and Ganglion cell layer average thickness on macular dense volume at one year (composite measure)

    D0 and one year

  • +1 more secondary outcomes

Study Arms (2)

patients

OTHER

patients with chronic optic neuropathy in multiple sclerosis

Procedure: • Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG

Controls

OTHER

healthy volunteers

Procedure: • Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients may have a clinically definite, laboratory-supported diagnosis of multiple sclerosis according to the Mac Donald criteria (2010).
  • All patients may present a chronic visual complaint.
  • All patients may present mild to moderate chronic optic neuropathy (cf infra)
  • All patients may not have recent acute optic neuritis (\<2 years)
  • All patients will be informed about the design and purpose of the study, and all will give their informed, written consent to the protocol, which may have been approved by the local ethics committee.
  • Age: \> 18
  • Able to understand the instructions
  • Having a health coverage
  • Able to sit down for 1 hour Diagnosis of mild to moderate chronic optic neuropathy
  • For the diagnosis of optic neuropathy, patients will have to meet 3 of the 6 next criteria:
  • Far Visual Acuity (ETDRS charts, 100% contrast) \< 85 letters
  • Far Visual Acuity (ETDRS charts, 2.5% contrast) \< 60 letters
  • Mean visual field defect on static perimetry\> 2dB
  • Mean pRNFL in OCT \< 80 µ.
  • Color vision score \> 35
  • +8 more criteria

You may not qualify if:

  • Ophthalmological
  • Other ophthalmological disorder that could impair corrected visual acuity (Maculopathy, Retinopathy…)
  • Ocular instability in primary position of gaze
  • Neurological
  • Ongoing seizure
  • Severe handicap that does not allow sitting down position for 1 hour
  • General
  • Unstable medical state
  • Severe renal insufficiency
  • Allergy to gadolinium
  • Claustrophobia
  • Implanted electrical stimulator (pace maker)
  • Metallic prosthesis or orthesis, cochlear implants
  • Intraocular foreign material
  • Pregnancy (on questioning)
  • +12 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON

France, BRON, 69677, France

Location

Related Publications (1)

  • Physiopathologie de la Neuropathie Optique Chronique de la SEP " Lucie ABOUAF, François DURAND-DUBIEF, Sandra VUKUSIC, Alain VIGHETTO, Caroline TILIKETE. Communication orale aux 3e journée des Neurosciences de l'Hôpital Neurologique le jeudi 24 septembre 2015, Institut des Sciences Cognitives, Lyon.

    BACKGROUND

MeSH Terms

Conditions

Optic Neuritis

Interventions

Visual AcuityVisual FieldsColor Vision

Condition Hierarchy (Ancestors)

Optic Nerve DiseasesCranial Nerve DiseasesNervous System DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Vision TestsDiagnostic Techniques, OphthalmologicalDiagnostic Techniques and ProceduresDiagnosisOcular Physiological PhenomenaVision, OcularSensationNervous System Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Caroline TILIKETE, MD

    Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON - France

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 25, 2014

First Posted

September 7, 2015

Study Start

September 1, 2014

Primary Completion

August 1, 2016

Study Completion

August 1, 2016

Last Updated

September 3, 2025

Record last verified: 2025-08

Locations